Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Vimang is a Cuban pharmaceutical brand and research entity primarily known for its line of natural antioxidant products derived from the bark of the mango tree (Mangifera indica). Developed by the Centro de Química Farmacéutica (CQF) and marketed by Labiofam under the BioCubaFarma umbrella, Vimang products are recognized for their anti-inflammatory, analgesic, and immunomodulatory properties. The product line includes tablets, creams, and syrups that target oxidative stress-related conditions and chronic inflammatory diseases. It is a key component of Cuba's natural and traditional medicine portfolio, with distribution in several Latin American and international markets. The active ingredient, mangiferin, has been extensively studied for its ability to inhibit inflammatory mediators and protect against cellular damage.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Vimang.